Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

miR-127-3p Inhibits Breast Cancer Cell Behaviors via Targeting Benzodiazepine Receptor-Associated Protein 1 (BZRAP1)

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

MicroRNA-1236-3p Inhibits Proliferation and Invasion of Breast Cancer Cells by Targeting ZEB1

MiR‐125a‐5p Functions As a Tumour Suppressor in Breast Cancer by Downregulating BAP1

MiR-526b Suppresses Cell Proliferation, Cell Invasion and Epithelial-Mesenchymal Transition in Breast Cancer by Targeting Twist1

Prognostic and biological significance of microRNA-127 expression in human breast cancer.

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

MiR-142-3p Functions As a Tumor Suppressor by Targeting RAC1/PAK1 Pathway in Breast Cancer.

miR-129-2-3p inhibits colon cancer cell proliferation by down-regulating the expression of BZW1

MiR-3194-3p Inhibits Breast Cancer Progression by Targeting Aquaporin1

MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion

miR-1296-5p decreases ERBB2 expression to inhibit the cell proliferation in ERBB2-positive breast cancer

MicroRNA-423 Drug Resistance and Proliferation of Breast Cancer Cells by Targeting ZFP36

A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.

miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells

Mirna-24-3p Promotes Cell Proliferation and Inhibits Apoptosis in Human Breast Cancer by Targeting P27kip1.

MicroRNA-34a Suppresses Breast Cancer Cell Proliferation and Invasion by Targeting Notch1

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors

Mir-124-3p Functions As a Tumor Suppressor in Breast Cancer by Targeting CBL

MicroRNA-671-3p Inhibits the Development of Breast Cancer: A Study Based on in Vitro Experiments, In-House Quantitative Polymerase Chain Reaction and Bioinformatics Analysis.

microRNA-944 inhibits breast cancer cell proliferation and promotes cell apoptosis by reducing SPP1 through inactivating the PI3K/Akt pathway